The cardioprotective role of beta-blockers in patients with diabetes mellitus.
This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded.
Landray
M J
MJ
Division of Medical Sciences, University of Birmingham, Birmingham, UK.
Toescu
V
V
Kendall
M J
MJ
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D003327:Coronary Disease / Q000209:etiology* / Q000517:prevention & control*; D016757:Death, Sudden, Cardiac; D048909:Diabetes Complications; D006801:Humans; D010818:Practice Patterns, Physicians'; D011446:Prospective Studies
D000319:Adrenergic beta-Antagonists